marketing-medtech

**Country:** Norway (Oslo)
**Founder:** William Vossgård — CEO & Co-founder
**Background:** serial_entrepreneur | verified: True — William Vossgård is Co-Founder & CEO of Noteless (Oslo, Norway), an AI clinical documentation startup founded in 2023 (first product launched June 2024; raised EUR 3.5M seed in Nov 2025). He holds an MSc in Industrial Economics and Technology Management and studied at DTU - Technical University of Denmark. Before Noteless he co-founded VISOAL, a Norwegian land-based salmon-farming venture (connected to Norwegian Mountain Salmon), where he worked as co-founder / technology project manager. Having co-founded at least two companies (VISOAL and Noteless), the 'serial entrepreneur' characterization is supported.
**Stage / fundraise:** Seed-stage, founded 2023, first product launched June 2024; ~35 employees, scaling commercially. / Raised €3.5M seed in Nov 2025 (Redstone, Futurum Ventures, Farvatn Venture).
**Regulatory trigger:** Largely BEHIND them: company states it is "CE-marked as a medical device and ISO-certified" (per noteless.com/en/about). The MDR/IEC 62304 milestone OmDev's compliance engine targets is already cleared, weakening the regulatory hook. Ongoing burden = multi-country expansion (UK, DE, NL) and maintaining the technical file.
**Email:** post@noteless.no (confidence medium) — post@noteless.no is the published general/contact inbox on noteless.com/en/about (along with phone +47 403 05 884). No published direct address for William Vossgård was found; a CEO-direct guess (e.g., william@noteless.no) would be pattern-only and is not asserted. Confidence is medium because the confirmed address is a shared inbox, not the founder's personal email.
**LinkedIn:** https://no.linkedin.com/in/williamvossgard **Website:** https://www.noteless.com
**Score:** 5 -> Tier C
**Hook:** Limited leverage. The standard OmDev pitch (tech team + dedicated CTO + IEC 62304/MDR compliance engine, ~3x cheaper than in-house) lands poorly here: Noteless already has a CTO co-founder, an in-house engineering+AI team, and is CE-marked/ISO-certified, and just raised to build engineering capacity internally. The only honest angle is overflow/surge capacity for fast multi-country localization or specific compliance-evidence (SOUP register + traceability) to ease ongoing MDR technical-file upkeep during EU expansion — but this is a weak, non-urgent need against a well-resourced builder. Recommend deprioritize.

---

## Founder & background
William Vossgård is CEO & co-founder of Noteless; he studied at DTU (Technical University of Denmark) and previously co-founded VISOAL — a serial entrepreneur with a technical/engineering background, NOT finance or insurance ([Crunchbase](https://www.crunchbase.com/person/william-vossg%C3%A5rd), [LinkedIn](https://no.linkedin.com/in/williamvossgard)).
The team is deliberately full-stack: Mikkel Dahl Slettebø is CTO & co-founder, Dr. Sarankan Sivakanesan is the clinical co-founder, and the org already lists 7+ software engineers plus a dedicated AI engineer ([about page](https://www.noteless.com/en/about)).

## Funding & momentum
Founded 2023, first product launched June 2024; ~35 employees across Norway, Denmark and the Netherlands. Raised a €3.5M seed in November 2025 led by Redstone, with Futurum Ventures and Farvatn Venture ([EU-Startups](https://www.eu-startups.com/2025/11/norwegian-healthtech-startup-noteless-raises-e3-5-million-to-tackle-doctor-burnout/), [Tech.eu](https://tech.eu/2025/11/27/noteless-gains-eur35m-to-free-doctors-from-administrative-burden/)).
Strong traction — 100k+ consultations/week, 3M+ processed, ~3,000 paying clinicians (1 in 4 Norwegian GPs). Crucially, the round is explicitly earmarked to strengthen in-house AI engineering and fund EU expansion.

## Product & regulatory
Ambient AI clinical-documentation / medical scribe (SaMD): speech-to-structured-notes during consultations, multilingual, across GP/physio/psychology specialties. Already live in NO, DK, NL, UK, DE.
The MDR/IEC 62304 hook is largely closed — the company states it is "CE-marked as a medical device and ISO-certified" ([about page](https://www.noteless.com/en/about)), so OmDev's compliance-evidence pipeline addresses a need they have already met.

## Pain & buying signals
This is a weak Dev-as-a-Service fit. Disqualifiers: a CTO co-founder, an in-house engineering + AI team, fresh capital aimed at building engineering capacity internally, and CE/ISO already achieved. There is no non-CTO gap and no imminent unmet regulatory milestone.
Residual (low-urgency) needs: surge capacity for rapid multi-country localization and ongoing MDR technical-file upkeep during EU scale-up.

**Why OmDev fits:** Honestly, marginal. The core OmDev value props (dedicated CTO, build the team ~3x cheaper, compliance engine for an upcoming CE/MDR milestone) are each already covered internally at Noteless. The only credible angle is overflow engineering/localization capacity or supplemental SOUP-register + requirements-to-test traceability to lighten technical-file maintenance — a soft, non-urgent pitch against a well-funded, well-staffed builder. Recommendation: Tier C, deprioritize for outreach.

---
**Sources:** https://www.eu-startups.com/2025/11/norwegian-healthtech-startup-noteless-raises-e3-5-million-to-tackle-doctor-burnout/ · https://www.crunchbase.com/organization/noteless · https://www.crunchbase.com/person/william-vossg%C3%A5rd · https://no.linkedin.com/in/williamvossgard · https://www.noteless.com/en/about · https://tech.eu/2025/11/27/noteless-gains-eur35m-to-free-doctors-from-administrative-burden/ · https://jobs.noteless.com/people/3462445-william-vossgard